http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2005318369-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_89e4cbfcdadd467d1ec0397d11d93055 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-112 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-96455 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2005-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75d4b1a6cea4b805ddc88d1a092c0530 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51b7b30bd11ff49e1f322a39121abd68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc5dcdaed7029feacf276e987ba179e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a27df7af3d3e0476b1d19d15bef14694 |
| publicationDate | 2012-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2005318369-B2 |
| titleOfInvention | mRNA ratios in urinary sediments and/or urine as a prognostic and/or theranostic marker for prostate cancer |
| abstract | Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value. |
| priorityDate | 2004-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 285.